3-羟基哌啶-1-羧酸甲酯 | 80613-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-羟基哌啶-1-羧酸甲酯
• 中文别名: 3-羟基-1-哌啶羧酸甲酯
• 英文名称: 3-hydroxypiperidine-1-carboxylic acid methyl ester
• 英文别名: (R,S)-methyl 3-hydroxypiperidine-1-carboxylate；(RS)-methyl-3-hydroxypiperidine-1-carboxylate；N-carboxymethyl-3-hydroxypiperidine；N-carbomethoxy-3-hydroxypiperidine；methyl 3-hydroxy-tetrahydro-1(2H)-pyridinecarboxylate；Methyl 3-hydroxypiperidine-1-carboxylate
• CAS: 80613-04-3
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: WTXSKBFLNOWQNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-羟基哌啶-1-羧酸甲酯 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以88%的产率得到1-哌啶 羧酸-3-氧代-甲酯
  参考文献：
  名称：

  [EN] NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS
  [FR] NOUVEAUX PROMÉDICAMENTS À BASE D'ACIDE 5-AMINOLÉVULINIQUE SERVANT À EFFECTUER UNE THÉRAPIE PHOTODYNAMIQUE ET UN DIAGNOSTIC PHOTODYNAMIQUE

  摘要：

  提供了一个化合物，其化学式为（I）或（II）及其盐，其中R1是亚胺或烷基化亚胺，所述亚胺或烷基化亚胺包括一条或分支的碳链长度为C1至C5的烷基基团；R2分别为（a）链长为C1-7的未取代或取代的线性或分支烷基基团；（b）芳基取代的烷基基团，其中所述芳基取代，（c）烷氧基取代的烷基基团，其中所述烷氧基被甲氧基或烷氧基取代的烷氧基取代；或（d）一个H原子；其中（a）和（b）中的取代基选择自羟基、烷氧基、酰氧基、烷氧羰氧基、氨基、芳基、硝基、氧化物和氟基。R3和R4是碳链长度为C1至C6的线性或分支烷基基团，构成一个缩醛或环缩醛。所述化合物可用于制造药物。

  公开号：

  WO2010024775A1
• 作为产物：
  描述：

  甲基3,4-二氢-1(2H)-吡啶羧酸酯 在 sodium tetrahydroborate 、 双氧水 作用下， 生成 3-羟基哌啶-1-羧酸甲酯
  参考文献：
  名称：

  Electroorganic chemistry. 60. Electroorganic synthesis of enamides and enecarbamates and their utilization in organic synthesis

  摘要：

  DOI：

  10.1021/ja00388a037

文献信息

• [EN] NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS<br/>[FR] NOUVEAUX PROMÉDICAMENTS À BASE D'ACIDE 5-AMINOLÉVULINIQUE SERVANT À EFFECTUER UNE THÉRAPIE PHOTODYNAMIQUE ET UN DIAGNOSTIC PHOTODYNAMIQUE
  申请人：SWEDISH PHARMA AB

  公开号：WO2010024775A1

  公开（公告）日：2010-03-04

  There is provided a compound of Formula (I) or (II) and salts thereof wherein R1 is an imine or an alkylated imine, said imine or alkylated imine comprising a linear or branched alkyl group of length C1 to C5; R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7; (b) an aryl substituted alkyl group, wherein said aryl group is substituted, (c) an alkoxy substituted alkyl group, wherein said alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group,; or (d) an H atom; wherein said substituents in (a) and (b) are selected from hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo and fluoro groups. R3 and R4 are linear or branched alkyl groups of length C1 to C6 constituting a ketal or a cyclic ketal. The compounds claimed may be used for the manufacture of a medicament.

  提供了一个化合物，其化学式为（I）或（II）及其盐，其中R1是亚胺或烷基化亚胺，所述亚胺或烷基化亚胺包括一条或分支的碳链长度为C1至C5的烷基基团；R2分别为（a）链长为C1-7的未取代或取代的线性或分支烷基基团；（b）芳基取代的烷基基团，其中所述芳基取代，（c）烷氧基取代的烷基基团，其中所述烷氧基被甲氧基或烷氧基取代的烷氧基取代；或（d）一个H原子；其中（a）和（b）中的取代基选择自羟基、烷氧基、酰氧基、烷氧羰氧基、氨基、芳基、硝基、氧化物和氟基。R3和R4是碳链长度为C1至C6的线性或分支烷基基团，构成一个缩醛或环缩醛。所述化合物可用于制造药物。
• C(6)-Alkylation of 3-Hydroxypiperidine via Reductive and Homolytic Cleavage of N,S-Acetals
  作者：Timothy Gallagher、Marc Bartels、Julian Zapico

  DOI：10.1055/s-2004-832846

  日期：——

  N-Carboxymethyl 3-hydroxypiperidine (6) undergoes substitution at C(6) via reductive cleavage of N,S-acetal 8a with lithium naphthalenide (LN) and trapping of the resulting carbanionic intermediate 9 with different electrophiles to give adducts 10. N,S-Acetal 8a also undergoes C-S homolysis and trapping of the resulting radical provides an alternative entry to 2-substituted-5-­hydroxypiperidines.

  N-Carboxymethyl 3-hydroxypiperidine (6) 通过 N,S-乙缩醛 8a 与萘化锂（LN）的还原裂解在 C(6)处发生取代反应，并通过不同的亲电体捕获生成的碳阴离子中间体 9，从而得到加合物 10。N,S-乙缩醛 8a 还会发生 C-S 均解，由此产生的自由基的捕获为 2-取代-5-羟基哌啶提供了另一种入口。
• Benzimidazole derivatives
  申请人：——

  公开号：US20040044056A1

  公开（公告）日：2004-03-04

  This invention relates to the compounds represented by a general formula [I]: 1 [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C 3 -C 20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及由一般式[I]表示的化合物：1[其中，A1和A2表示选择性氟代甲基或类似物；B表示卤素，氰基，低碳烷基或类似物；D表示选择性取代的杂环基团或类似物；G表示C3-C20脂肪族基团，例如脂环族基团]。这些化合物由于对痛觉受体具有高亲和力而抑制了痛觉肽活性，并且可用作镇痛剂，抗肥胖剂，脑功能改善剂，治疗阿尔茨海默病和痴呆症的药物，治疗精神分裂症和神经退行性疾病的药物，抗抑郁剂，治疗尿崩症，多尿症，低血压等的药物。
• BENZIMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1342717A1

  公开（公告）日：2003-09-10

  This invention relates to the compounds represented by a general formula [I]:    [in which A1 and A2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C3-C20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及通式[I]所代表的化合物： [其中 A1 和 A2 代表任选氟取代的甲基或类似物；B 代表卤素、氰基、低级烷基或类似物；D 代表任选取代的杂环基团或类似物；G 代表 C3-C20 脂肪族基团，例如脂环族基团]。这些化合物由于与痛觉素受体的高亲和力而抑制痛觉素的活性，可用作镇痛剂、抗镇静剂、改善大脑核心功能的药物、治疗老年痴呆症和痴呆症的药物、治疗精神分裂症和神经退行性疾病的药物、抗抑郁剂、治疗糖尿病、多尿、低血压等。
• GABA uptake inhibitors. Syntheses and structure—activity studies on GABA analogues containing diarylbutenyl and diarylmethoxyalkyl N-substituents
  作者：E Falch、P Korgsgaard-Larsen

  DOI：10.1016/0223-5234(91)90214-8

  日期：1991.1

  A number of analogues of GABA or B-alanine containing 4,4-diphenyl-3-butenyl (DPB), benzhydryl ethyl ether (BEE), or benzhydryl propyl ether N-substituents have been synthesized and tested as inhibitors of synaptosomal GABA uptake. N-methylation of these analogues resulted in increased potency and reduced pKa II values of the reaction products 4a and 8a, respectively. Incorporation of the alkyl groups of the benzhydryl alkyl ether moieties of N-methyl-N-BEE-B-alanine (12), N-methyl-N-BEE-GABA (8a), or the benzhydryl propyl ether analogue of N-methyl-GABA (10) into the cyclized piperidine analogues gave the less active compounds 17, 18, and 19, respectively. This loss of in vitro activity was most pronounced for the GABA analogues 18 and 19. These results suggest that the basic character of the amino groups as well as the conformational flexibility of the spacer-arm connecting the amino acid 'heads' and the aromatic moieties of this class of GABA uptake inhibitors are factors of importance for GABA uptake affinity.